Study Stopped
PI is leaving the institution and study is being terminated with the IRB.
Implications of Circadian Variation of Human Endocannabinoid Levels on Obesity Risk
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The purpose of this study is to examine how the timing of eating changes 24hr profiles of lipids involved in eating for pleasure and how the body makes and uses energy (metabolism).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Oct 2026
Typical duration for not_applicable obesity
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 12, 2016
CompletedFirst Posted
Study publicly available on registry
December 22, 2016
CompletedStudy Start
First participant enrolled
October 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2029
Study Completion
Last participant's last visit for all outcomes
October 1, 2029
January 12, 2026
January 1, 2026
3 years
December 12, 2016
January 8, 2026
Conditions
Outcome Measures
Primary Outcomes (4)
Change in the time of acrophase of the 24hr eCB profile
A shift in the timing ( time of day, h:mm) of the peak (acrophase) of the eCB rhythm.
Baseline to Day 38
Change in appetite/hunger and reward-related eating scores
The change in the temporal profile of hunger and appetite ratings (measured at 6 time points over a 24hr period) as well as reward-related eating (RRE) from baseline to after the intervention. The ratings of hunger and appetite, and RRE from baseline to intervention will be measured by number rating, on a 10 point scale for hunger and appetite and agree/don't agree or a 5-point scale for the RREs.
Baseline to Day 38
Change in glucose tolerance
The change in glucose tolerance from baseline to after the intervention will be measured. Glucose outcomes from CGM include Mean Absolute Glucose (MAG - mg/dl), Coefficient of Variation (CV - mg/dl), Standard Deviation (SD-mg/dl), Area Under the Curve (AUC - mg/dl), Time Spent in Range (TIR - minutes), Continuous Overall Net Glycemic Action (CONGA - (mg/dl) per minutes ).
Baseline to Day 38
Change in insulin sensitivity
The change in insulin sensitivity from baseline to after the intervention will be measured. Insulin sensitivity measurements from the MMT include area under the curve for insulin (pmol/L) and cpeptide (pmol/L) as well as peak values (pmol/L).
Baseline to Day 38
Secondary Outcomes (1)
Change in Weight
Baseline to Day 38
Study Arms (2)
Early Total Caloric Intake
EXPERIMENTALThe Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
Late Total Caloric Intake
ACTIVE COMPARATORThe Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
Interventions
Provide subjects a regimented amount of calories at each meal.
Provide subjects a regimented amount of calories at each meal.
Eligibility Criteria
You may qualify if:
- self-report sleeping between 7-hrs/night and 9-hrs/night, between 22:00 and 08:00
- no previously diagnosed sleep disorders (including obstructive sleep apnea (OSA))
- no existing diagnosis of prediabetes or diabetes
- no history of endocrine dysfunction
- no history of psychiatric, cardiovascular, or eating disorders
- must not have a gastro-intestinal disease that requires dietary adjustment
- currently taking no medications (including birth control)
You may not qualify if:
- drug and nicotine use, habitual alcohol use of more than 2 drinks per day, and caffeine intake of more than 300 mg per day
- anyone who has participated in medically managed weight loss program within the past year
- anyone who has undergone bariatric surgery
- must not have dietary restrictions
- must not work night shifts or crossed any time zones in the month prior to the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erin Hanlon, PhD
University of Chicago
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 12, 2016
First Posted
December 22, 2016
Study Start (Estimated)
October 1, 2026
Primary Completion (Estimated)
October 1, 2029
Study Completion (Estimated)
October 1, 2029
Last Updated
January 12, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
There is currently no plan to make IPD available to other researchers.